Sign in

    Francis DiGiovanna

    Research Analyst at TD Securities

    Francis DiGiovanna is an Equity Research Associate specializing in energy and mobility technology at TD Cowen, where he analyzes companies such as Ovintiv Inc. and provides detailed sector research for institutional clients. He has contributed to several high-profile energy sector earnings calls and has a reputation for rigorous analysis supporting senior research teams. Prior to joining TD Cowen, DiGiovanna held research roles at Cowen Inc., focusing on similar coverage areas, and is recognized for his expertise in the evolving energy and mobility sectors. Francis holds professional FINRA registrations and securities licenses commensurate with his research analyst responsibilities.

    Francis DiGiovanna's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Francis DiGiovanna's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q1 2025

    Question

    Francis DiGiovanna, on for Tyler Van Buren, asked for the rationale behind studying morning dosing versus evening dosing in the fourth cohort of the atumelnant trial.

    Answer

    Dr. R. Struthers, CEO, explained the goal was to explore future optionality for patient convenience. He added that it is important to understand the drug's effect in relation to the strong diurnal rhythm of the HPA axis in CAH patients to ensure timing does not significantly impact efficacy.

    Ask Fintool Equity Research AI